New drug targets inflammation in heart and kidney patients

NCT ID NCT06675175

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new drug called AZD4144 in 29 people who have both heart disease and chronic kidney disease. The main goal was to see if the drug is safe and if it lowers certain markers of inflammation in the blood. The study compared the drug against a placebo over 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD4144
What this could lead to: If successful, this could point toward a new way to reduce inflammation in people with both heart and kidney disease.
What could go wrong: This is a very early Phase 1 trial with only 29 people, so it is mainly checking safety, not yet proving the drug works. Many early-stage drugs do not move forward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE CHRONIC KIDNEY DISEASE

Contacts and locations

Locations

Research Site

Glendale, California, 91203, United States
Research Site

Daytona Beach, Florida, 32117, United States
Research Site

Jacksonville, Florida, 32216, United States
Research Site

Miami, Florida, 33125, United States
Research Site

Port Orange, Florida, 32127, United States
Research Site

Tampa, Florida, 33603, United States
Research Site

Farmington Hills, Michigan, 48334, United States
Research Site

The Bronx, New York, 10455, United States
Research Site

Sherman, Texas, 75092, United States
Research Site

Pleven, 5800, Bulgaria
Research Site

Sofia, 1527, Bulgaria
Research Site

Gyöngyös, 3200, Hungary
Research Site

Kistarcsa, 2143, Hungary
Research Site

Bucharest, 11658, Romania
Research Site

Cluj-Napoca, 400006, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.